<DOC>
	<DOCNO>NCT01160601</DOCNO>
	<brief_summary>This randomize , open-label , multicenter , phase 2 study compare Paclitaxel/Carboplatin without bavituximab patient previously untreated locally advanced metastatic non-small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Study Paclitaxel/Carboplatin With Without Bavituximab Previously Untreated Non Small-Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Key Adults 18 year age life expectancy least 3 month . Histologically cytologically confirm stage IIIB stage IV nonsquamous NSCLC previously treat systemic chemotherapy . Measurable disease Response Evaluation Criteria Solid Tumors ( RECIST , Version 1.1 ) . Adequate hematologic , renal hepatic function . PT / INR ≤ 1.5 × ULN , aPTT ≤ 1.5 × ULN Ddimer ≤ 3 × ULN . Key Squamous cell , small cell , mixed histology . Known history bleed diathesis coagulopathy . Cavitary tumor tumor abut large blood vessel . Bleeding : Clinically significant bleeding , gross hematuria , GI bleed hemoptysis , within 12 month Screening . Venous thromboembolic event ( e.g. , deep vein thrombosis pulmonary thromboembolism ) within 6 month Screening . Ongoing therapy oral parenteral anticoagulant . Concurrent estrogens , antiestrogens progesterone compound . Grade 2 high peripheral neuropathy . Radiotherapy within 2 week precede Study Day 1 . Symptomatic clinically active brain metastasis . Major surgery within 4 week Study Day 1 . Uncontrolled intercurrent disease ( e.g. , diabetes , hypertension , thyroid disease ) . Symptomatic coronary artery disease , cerebrovascular accident , transient ischemic attack , myocardial infarction , unstable angina pectoris within 6 month Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>lung cancer</keyword>
	<keyword>non small cell lung cancer</keyword>
	<keyword>bavituximab</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>